Italia Markets closed

Bavarian Nordic A/S (0DPB.L)

LSE - LSE Prezzo differito. Valuta in DKK.
Aggiungi a watchlist
326,10+20,17 (+6,59%)
Alla chiusura: 08:01AM BST
Schermo intero
Chiusura precedente305,93
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno306,50 - 324,60
Intervallo di 52 settimane171,45 - 410,70
Media Volume44.021
Beta (5 anni mensile)1,33
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve

    COPENHAGEN, Denmark, September 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox vaccine to rescEU, a strategic reserve within the European Union (EU). This order follows an initial contract awarded in June 2023 and is also for delivery in 2024. The vaccines will be stockpiled in another EU country thus expanding the EU’s capability to respond to biological threats and emergencie

  • GlobeNewswire

    Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

    COPENHAGEN, Denmark, September 4, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NameLuc Debruyne2.Reason for the notificationa)Position/statusChairman of the Board of Directors of Bavarian Nordic A/Sb)Initi

  • GlobeNewswire

    Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program

    ABNCoV2 and the comparator vaccine demonstrated a reduced level of neutralizing antibodies against a circulating variant (Omicron XBB.1.5) in Phase 3 study.cVLP platform has proven its ability to induce strong and lasting immunity against the target virus, but Bavarian Nordic sees no commercial opportunity for the vaccine, as the platform is not suitable for quick adaptions to emerging variants.The Company will continue its dialogue with authorities on how best to leverage the learnings about th